About this episode
Pharmeasy, once the highest-valued Indian healthcare startup, is planning to raise money in a new round of funding at a 90% markdown from its previous valuation.
From $5.6 billion to $500 million.
All because Pharmeasy had to take another debt to pay off its previous debt. The second time though, interest rates were not zero.
What's going on?
Tune in.
Recommendation
Byju’s is looking like a hedge fund
The tail of acquisitions wagging India’s funding dog
Daybreak is produced from the newsroom of The Ken, India’s first subscriber-only business news platform. Subscribe for more exclusive, deeply-reported, and analytical business stories.
Get every episode summarized
Each time Daybreak publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Daybreak
This week in AI: activist robots, doom-laden researchers — so who's the good guy...
Daybreak
India has more tourists than ever. So why is tourism in trouble?
Daybreak
The Government sold Air India to escape its problems. The fix is to buy back in
Daybreak
Nykaa cracked fashion at last. Myntra sees no reason to panic
Daybreak